Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 7/20 | 0.37 |
| ▸ | PTGER2 | P43116 | 7/20 | 0.37 |
| ▸ | PTGER1 | P34995 | 7/20 | 0.37 |
| ▸ | PTGER3 | P43115 | 6/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3595561 | 1.00 | KDM4E (0.38) | KDM4ELMNAPTGER4PTGER2PTGER1 | |
| SCHEMBL3612380 | 0.89 | PTPN1 (0.37) | KDM4ELMNAPTGER1PTPN1ALDH1A1 | |
| SCHEMBL3610906 | 0.83 | ALDH1A1 (0.34) | KDM4EAKR1C3ALDH1A1 | |
| SCHEMBL3610914 | 0.83 | ALDH1A1 (0.34) | KDM4EAKR1C3ALDH1A1 | |
| SCHEMBL3600881 | 0.83 | HTR2A (0.37) | PTGER1PTPN1HTR2AHTR2CFFAR4 | |
| SCHEMBL3599357 | 0.78 | CYP1A2 (0.45) | KDM4ELMNAPTGER1PTPN1ALDH1A1 | |
| SCHEMBL3613728 | 0.74 | L3MBTL1 (0.40) | PTGER1PTPN1PKMHTR2AHTR2C | |
| SCHEMBL3608298 | 0.71 | — | — | |
| SCHEMBL3605127 | 0.70 | POLB (0.43) | LMNAPTGER1PTPN1PKMHTR2A | |
| SCHEMBL3607405 | 0.66 | ALDH1A1 (0.42) | KDM4ELMNAPTGER4PTGER2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016396-A1 | PYRAZOLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128138-A1 | PYRAZOLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016396-A1 | PYRAZOLE COMPOUND | SLC5A1, SLC5A2, GLP1R | KDM4E 2049/4885LMNA 4306/4885PTGER4 2282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.